ReviewFrontiers in immunology2025
Unveiling the dual role of circulating tumor cells in colorectal cancer immunotherapy: a comprehensive review of biomarker utility and immune microenvironment crosstalk.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Electrochemical Biosensors for Circulating Tumor Cells and ctDNA: Emerging Strategies for Precision Oncology.Annals of biomedical engineering · 2026Review
- AI-driven dual-task prediction model for co-stratifying efficacy and toxicity in NSCLC immunotherapy.PLOS digital health · 2026Article
- Interactions Between Circulating Tumor Cells and the Immune System in Colorectal Cancer: Friends or Foes?Cancers · 2026Review
- Hyperthermia enhances the efficacy of PD-1 inhibitor plus chemotherapy in PD-L1 CPS-negative advanced gastric cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) has the highest incidence in the Asia-Pacific region, accounting for 51.8% of global cases. Despite early screening methods like colonoscopy, CT, and MRI, 20-25% of patients are diagnosed at advanced stages, with some having liver metastasis. Personalized treatments, including targeted and immunotherapy, are crucial for metastatic or recurrent CRC. Circulating tumor cells (CTC), emerging as a non-invasive biomarker, play a key role in assessing metastasis and prognosis. CTC count is linked to CRC stage, microsatellite instability (MSI-H), and drug resistance, and is valuable in evaluating the response to immune checkpoint inhibitors (ICIs). Immune cells in the tumor microenvironment influence CTC behavior, impacting metastasis, immune evasion, and resistance. Advances in CTC detection and genetic markers offer new possibilities for early diagnosis and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.